David Cook appointed Chief Financial Officer of Biotie
David Cook, (age 45), has been appointed Chief Financial Officer (CFO) of Biotie Therapies Corp., effective February 25, 2013. He will become a member of the Group's management team and will report to Timo Veromaa, President and Chief Executive Officer. David will be based at the Company's headquarters in Turku, Finland.
Kristian Rantala, current interim CFO, will resume his prior duties as Vice President, Finance and Administration, Finland.
David Cook, a British native, has extensive industry expertise in life science enterprises in finance, strategy, investor relations and M&A. Previously David was CFO, International, of Jazz Pharmaceuticals, Inc., a NASDAQ listed company and before this CFO of EUSA Pharma Inc., which was acquired by Jazz Pharmaceuticals in mid-2012. Before joining EUSA David was Group Financial Controller at Zeneus Pharma Limited and prior to that worked for PricewaterhouseCoopers in the United Kingdom and Australia. David is a qualified chartered accountant and graduated from the University of Oxford with a degree in Chemistry.
Timo Veromaa, CEO of Biotie:
"I am very pleased that David is joining Biotie's management team and we look forward to his contributions to the growth of the group. As Biotie continues to mature as a company, David's extensive experience in building profitable biotech businesses will be extremely valuable."